Table 3.
Time to detection of ADAbs.
| Author | Disease | Number of patients | ADAbs first detected | Biologic therapy |
|---|---|---|---|---|
| Baert and colleagues58
Magdelaine-Beuzelin and colleagues59 |
CD | 125 | After first infusion | IFX |
| Vermeire and colleagues37 | CD | 174 | After first infusion | IFX |
| Schatz and colleagues52 (CA) | CD and UC | 50 | Before second infusion | IFX |
| Ungar and colleagues41 | CD and UC | 125 | 2 weeks | IFX |
| Steenholdt and colleagues60
Steenholdt and colleagues51 |
CD and UC | 180 | Third infusion | IFX |
| Vande Casteele and colleagues47 | CD and UC | 90 | 4 weeks/fourth infusion | IFX |
| Vande Casteele and colleagues53 (CA) | CD and UC | 57 | 7 weeks | IFX |
| Ainsworth and colleagues38 | CD | 33 | 8 weeks | IFX |
| Vande Casteele and colleagues54 (CA) | CD and UC | 52 | 8 weeks/third infusion | IFX |
| Rosenthal and colleagues55 (CA) | CD and UC | 38 | <14 weeks | IFX |
| Colombel and colleagues50 | CD | 219 | 30 weeks | IFX |
| Hanauer and colleagues56 | CD | 299 | 2 weeks | ADM |
| West and colleagues61 | CD | 25 | 10 weeks | ADM |
| Karmiris and colleagues26
Baert and colleagues57 |
CD | 148 | 12 weeks | ADM |
| Sandborn and colleagues49 | UC | 721 | 6 weeks | GLM |
ADAbs, anti-drug antibodies; ADM, adalimumab; CA, conference abstract; CD, Crohn’s disease; GLM, golimumab; IFX, infliximab; UC, ulcerative colitis.